Comparative Pharmacology
Head-to-head clinical analysis: HI COR versus LOTEPREDNOL ETABONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HI COR versus LOTEPREDNOL ETABONATE.
HI-COR vs LOTEPREDNOL ETABONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin and leukotriene synthesis.
Corticosteroid with high glucocorticoid receptor affinity; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
0.1-0.2 mg/kg intravenously once.
0.5% ophthalmic suspension: 1-2 drops into affected eye(s) four times daily. In severe cases, may be increased to 1-2 drops every hour during the first week, then taper.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours. Clinical context: Short half-life requires frequent dosing for sustained effect; accumulation possible in renal impairment.
Terminal elimination half-life is 2.2-4.3 hours; clinical context: supports twice-daily dosing in ophthalmic use, with minimal systemic accumulation.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with biliary/fecal excretion contributing 20-30%.
Primarily hepatic metabolism; metabolites excreted in urine (approximately 80% as inactive metabolites) and feces (15-20%). Less than 1% excreted unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid